60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened
60 Degrees Pharmaceuticals, Inc. (ticker: SXTP) filed a Current Report on Form 8-K dated January 8, 2026 to disclose an investor presentation made available in connection with a webinar hosted by RedChip Companies, Inc. The presentation, furnished as Exhibit 99.1, includes updated information on the company’s clinical development timelines and its regulatory strategy. The filing was made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).

Key Details

• The 8-K was filed January 8, 2026 and the investor presentation is included as Exhibit 99.1.
• Presentation was shared in connection with a RedChip Companies, Inc. webinar.
• Content includes updated clinical development timelines and the company’s regulatory strategy (no new financial results or material agreements were reported).
• Disclosure was made under Regulation FD to broadly distribute the information.

Why It Matters
For investors, updated clinical timelines and regulatory strategy are potential catalysts because they clarify expected milestones and paths to regulatory review for the company’s drug candidates. The 8-K does not report earnings, new financing, or executive changes—rather, it makes the presentation publicly available so investors and analysts can review the latest development and regulatory plans. Review the furnished Exhibit 99.1 for specifics on timing and regulatory steps.